전 세계 다중 암 조기 발견 시장 규모는 2023년 9억 3,590만 달러에서 예측 기간 동안 16.30%의 CAGR로 2034년 51억 5,350만 달러로 급증할 것으로 예상됩니다.
이 시장은 전 세계 암 발병률 증가, 조기 진단에 대한 수요 증가, 액체 생검 및 유전체 기술의 발전 등을 주요 요인으로 꼽을 수 있습니다. 또한, 정밀의료에 대한 투자 확대, 혈액 기반 스크리닝 검사의 채택 확대, 예방적 건강관리의 추진도 시장 성장에 기여하고 있습니다.
| 주요 시장 통계 | |
|---|---|
| 예측 기간 | 2024-2034년 |
| 2024년 평가 | 11억 3,830만 달러 |
| 2034년 예측 | 51억 5,350만 달러 |
| CAGR | 16.3% |
세계 다중 암 조기 발견 시장은 암 조기 발견이 더 높은 생존율과 더 나은 치료로 이어진다는 인식이 확산되고, 주요 시장 참여자들 간의 협력과 전략적 파트너십이 확대되면서 다중 암 조기 발견의 채택을 가속화하고 있다는 사실에 힘입어 큰 폭으로 성장하고 있습니다. 이 시장은 민간 기업과 학계 및 임상 연구 기관과의 강력한 협력 관계의 혜택을 누리고 있습니다. 이러한 협력 관계는 과학 연구와 실제 적용 사이의 간극을 메우는 데 도움이 되고 있습니다. 기업은 종종 자금, 기술, 상업화 전문 지식을 제공하고, 연구 기관은 과학적 지식, 검사 능력, 환자 데이터를 제공합니다.
기술별로는 차세대 염기서열분석기(NGS) 부문이 시장에서 우위를 차지:
기술별로는 NGS 부문이 2023년 가장 큰 점유율을 차지했으며, 예측 기간 동안 17.33%의 CAGR을 기록하여 2034년에는 34억 5,540만 달러 규모에 달할 것으로 예상됩니다. NGS는 간단한 혈액 샘플에서 순환 DNA(ctDNA) 및 기타 분자 시그니처를 포괄적으로 분석하여 여러 암의 비침습적이고 정확한 조기 발견을 촉진하고, 동시에 여러 암을 비침습적으로 정확하게 진단할 수 있게 해줍니다. 높은 처리량, 확장성, 희귀한 유전자 변이 검출 능력으로 여러 암을 조기에 발견할 수 있는 강력한 도구가 될 수 있습니다. 민감도와 데이터 분석의 개선으로 기술이 계속 발전함에 따라 NGS는 암 검진 및 맞춤형 의료를 변화시키는 데 중요한 역할을 할 것으로 보입니다.
검체 유형별로는 혈액 부문이 시장에서 우위를 차지:
검체 유형별로는 혈액 부문이 2023년에 가장 큰 점유율을 차지했으며, 예측 기간 동안 16.86%의 CAGR을 기록하여 2034년에는 45억 8,660만 달러에 달할 것으로 예상됩니다. 혈액은 침습성이 낮고, 채취가 용이하며, 종합적인 생물학적 정보를 제공할 수 있기 때문에 여러 암의 조기 발견을 위한 검체 유형으로 일반적으로 사용됩니다. 혈액에는 순환 종양 DNA(ctDNA), 순환종양세포(CTC), 단백질 및 기타 바이오마커가 포함되어 있어 초기 단계에서도 암의 존재를 나타낼 수 있습니다. 이러한 바이오마커는 유전자 돌연변이, 후생유전학적 변화 및 다양한 암과 관련된 기타 분자적 변화를 반영할 수 있습니다. 따라서 혈액 검체 유형은 조기 다발성 암을 검출하는 데 선호되고 있습니다.
세계의 다중 암 조기 발견 시장을 조사했으며, 주요 동향, 시장 영향요인 분석, 법·규제 환경, 기술개발·특허 동향, 사례 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별·주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
시장 분류
세분화 1 : 기술별
세분화 2 : 시료 유형별
세분화 3 : 최종사용자별
세분화 4 : 지역별
Introduction of Multi-Cancer Early Detection
The global multi-cancer early detection market, initially valued at $935.9 million in 2023, is set to witness substantial growth, projected to surge to $5,153.5 million by 2034, marking a remarkable compound annual growth rate (CAGR) of 16.30% over the period from 2024 to 2034. The market has been experiencing significant growth, primarily fuelled by the rising global cancer burden, increasing demand for early diagnosis, and advancements in liquid biopsy and genomic technologies. Moreover, growing investments in precision medicine, expanding adoption of blood-based screening tests, and the push for preventive healthcare also contribute to market growth.
Market Introduction
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2024 - 2034 |
| 2024 Evaluation | $1,138.3 Million |
| 2034 Forecast | $5,153.5 Million |
| CAGR | 16.3% |
The global multi-cancer early detection market has been experiencing significant growth, fueled by raising awareness among the population about early detection of cancer leading to higher survival chances and better treatment, along with growing collaborations and strategic partnerships among key market players, which are accelerating the adoption of multi-cancer early detection. The multi-cancer early detection market is benefiting from strong collaboration between private companies and academic or clinical research institutes. These collaborations help bridge the gap between scientific research and real-world applications. Companies often provide the funding, technology, and commercialization expertise, while research institutes contribute their scientific knowledge, testing capabilities, and patient data. For instance, in October 2023, HCA Healthcare, Inc., Sarah Cannon Cancer Institute, and GRAIL, Inc. announced a strategic collaboration to advance comprehensive cancer care through early detection. Therefore, the introduction of advanced services, collaboration, and partnerships contribute to the rapid development, validation, and adoption of multi-cancer early detection, which holds the potential to revolutionize cancer diagnosis, improve patient outcomes, and reduce healthcare costs globally.
Industrial Impact
The multi-cancer early detection market has significantly influenced the healthcare landscape, driven by key players such as GRAIL, Inc., Burning Rock Biotech Limited, Exact Sciences Corporation, and Freenome Holding, Inc. These companies are at the forefront, providing cutting-edge platforms for multi-cancer early detection.
Moreover, the market has been further shaped by strategic collaborations, mergers, and R&D investments, which enable companies to expand their global presence and introduce innovative solutions. With the increasing focus on understanding tissue architecture and disease mechanisms, the competitive landscape of the multi-cancer early detection market is dynamic, with innovation and customer-centric approaches driving differentiation and growth.
Market Segmentation for Multi-Cancer Early Detection Market:
Segmentation 1: by Technology
Next-Generation Sequencing (NGS) Segment to Dominate the Multi-Cancer Early Detection Market (by Technology)
Based on technology, the global multi-cancer early detection market was led by the next-generation sequencing (NGS) segment, which accounted for the largest share in 2023 and is expected to reach $3,455.4 million by 2034, registering a CAGR of 17.33% during the forecast period 2024-2034. NGS technology is rapidly advancing in the multi-cancer early detection market, offering unprecedented capabilities for identifying genetic mutations, epigenetic alterations, and other biomarkers associated with various cancer types. NGS enables comprehensive analysis of circulating DNA (ctDNA) and other molecular signatures from a simple blood sample, simultaneously facilitating non-invasive, accurate, and early detection of multiple cancers. Its high throughput, scalability, and ability to detect rare genetic variants make it a powerful tool in the early detection of multi-cancers. As technology continues to evolve, with improvements in sensitivity and data analysis, NGS is set to play a critical role in transforming cancer screening and personalized medicine.
Segmentation 2: by Sample Type
Blood Segment to Dominate the Multi-Cancer Early Detection Market (by Sample Type)
Based on sample type, the global multi-cancer early detection market was led by the blood segment, which accounted for the largest share in 2023 and is expected to reach $4,586.6 million by 2034, registering a CAGR of 16.86% during the forecast period 2024-2034. Blood is commonly used as a sample type for multi-cancer early detection due to its minimally invasive nature, ease of collection, and ability to provide comprehensive biological information. It contains circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), proteins, and other biomarkers that can indicate the presence of cancer, even at early stages. These biomarkers can reflect genetic mutations, epigenetic alterations, and other molecular changes associated with various cancers. Therefore, blood sample type is mostly preferred for early multi-cancer detection.
Segmentation 3: by End User
Hospital Segment to Dominate the Multi-Cancer Early Detection Market (by End User)
Based on end user, hospitals accounted for the largest share in 2023 and are expected to reach $3,865.1 million by 2034, registering a CAGR of 16.60% during the forecast period 2024-2034. The expansion of this segment is driven by the growing demand for hospitals that provide comprehensive services in a single location. A significant benefit of hospitals offering multi-cancer diagnostics is their ability to deliver test results promptly, even in emergencies. Continuous advancements in hospital laboratories are crucial to addressing the changing needs of patients, prompting many hospitals to broaden their diagnostic and treatment offerings.
Segmentation 4: by Region
In 2023, Europe region dominated the global multi-cancer early detection market, however, the Asia-Pacific region is expected to register the highest CAGR of 17.79% during the forecast period 2024-2034. The Europe multi-cancer early detection market is driven by increasing awareness of cancer prevention, rapid advancements in diagnostic technologies, and rising healthcare investments, which are key factors driving the market growth. Government-funded screening programs targeting multi-cancers have played a pivotal role in promoting the adoption of innovative diagnostic solutions. Additionally, the integration of cutting-edge technology, including next-generation sequencing, continues to improve detection accuracy and effectiveness, making early diagnosis more accessible and reliable.
Recent Developments in the Multi-Cancer Early Detection Market
Demand - Drivers, Challenges, and Opportunities
Market Drivers:
Increasing Incidence of Cancer Leading to Increased Demand for Early Detection: The increasing incidence of various solid tumors, including breast, lung, and colorectal cancers, serves as a primary driver for the growth of the multi-cancer early detection market globally. According to data published by GLOBOCAN, approximately 19.98 million cancer cases were reported in 2022, with projections estimating this number to rise to 24.1 by 2030. This alarming increase in cancer cases is anticipated to accelerate demand for advanced diagnostic tools as healthcare providers seek effective strategies for early detection and personalized treatment options. Early detection of cancer plays a critical role in improving survival rates and reducing the complexity of treatments. Many types of cancer, when detected in the early stages, are treatable and manageable, with higher chances of complete recovery. Additionally, early diagnosis improves survival and enhances patients' quality of life by minimizing the intensity of treatment required. Thus, the increasing incidence of cancer is expected to accelerate the demand for early cancer detection.
Market Challenges:
High Cost of Multi-Cancer Early Detection Tests: The high costs associated with multi-cancer early detection tests continue to restrain the growth of the multi-cancer early detection market, making these innovative tools inaccessible to many. Multi-cancer early detection tests provide broader cancer detection; hence, they come at a higher cost than traditional single-cancer tests. Moreover, limited insurance reimbursement for such tests further compounds the issue. For instance, most insurance providers in the U.S. do not yet cover MCED tests, leaving patients to pay out-of-pocket. This high financial burden restricts the accessibility of these technologies to affluent populations and limits their integration into public health programs. As a result, while these technologies show promise in detecting multiple cancers at early stages, their high price points hinder large-scale adoption, particularly in economically constrained healthcare systems.
Market Opportunities:
Integration of Artificial Intelligence in Multi-Cancer Early Detection: The integration of artificial intelligence (AI) into cancer screening has revolutionized early detection methods, significantly boosting the multi-cancer early detection market. These innovations play a key role in improving diagnostic process accuracy, speed, and cost-effectiveness, enabling better outcomes and transforming cancer care. Moreover, AI and data analytics are being leveraged to combine multiple diagnostic modalities, such as blood tests, imaging, and genetic analysis, creating a comprehensive multi-cancer early detection system.
How can this report add value to an organization?
Product/Innovation Strategy: The global multi-cancer early detection market has been extensively segmented based on various categories, such as technology, sample type, end user, and region.
Growth/Marketing Strategy: Mergers, acquisitions, and product launches accounted for the maximum number of key developments.
Competitive Strategy: The global multi-cancer early detection market has numerous established players with product portfolios. Key players in the global multi-cancer early detection market analyzed and profiled in the study involve established players offering products for multi-cancer early detection.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
Primary Research:
The primary sources involve industry experts in multi-cancer early detection, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
Secondary Research
Open Sources
The key data points taken from the secondary sources include:
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts, who have analyzed company coverage, product portfolio, and market penetration.
Some prominent names established in this market are: